keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimer biomarker

keyword
https://www.readbyqxmd.com/read/29679574/evidence-of-demyelination-in-mild-cognitive-impairment-and-dementia-using-a-direct-and-specific-magnetic-resonance-imaging-measure-of-myelin-content
#1
Mustapha Bouhrara, David A Reiter, Christopher M Bergeron, Linda M Zukley, Luigi Ferrucci, Susan M Resnick, Richard G Spencer
INTRODUCTION: We investigated brain demyelination in aging, mild cognitive impairment (MCI), and dementia using magnetic resonance imaging of myelin. METHODS: Brains of young and old controls and old subjects with MCI, Alzheimer's disease, or vascular dementia were scanned using our recently developed myelin water fraction (MWF) mapping technique, which provides greatly improved accuracy over previous comparable methods. Maps of MWF, a direct and specific myelin measure, and relaxation times and magnetization transfer ratio, indirect and nonspecific measures, were constructed...
April 18, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/29679161/present-and-future-of-ultra-high-field-mri-in-neurodegenerative-disorders
#2
REVIEW
Graziella Donatelli, Roberto Ceravolo, Daniela Frosini, Michela Tosetti, Ubaldo Bonuccelli, Mirco Cosottini
PURPOSE OF REVIEW: With a high signal-to-noise ratio, unparalleled spatial resolution, and improved contrasts, ultra-high field MR (≥ 7 T) has great potential in depicting the normal radiological anatomy of smaller structures in the brain and can also provide more information about morphological, quantitative, and metabolic changes associated with a wide range of brain disorders. By focusing attention on specific brain regions believed to be associated with early pathological change, or by more closely inspecting recognized foci of brain pathology, ultra-high field MR can improve the accuracy and sensitivity of neuroimaging...
April 20, 2018: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/29678753/human-apolipoprotein-e-genotype-differentially-affects-olfactory-behavior-and-sensory-physiology-in-mice
#3
Brett S East, Gloria Fleming, Kathy Peng, Jonas K Olofsson, Efrat Levy, Paul M Mathews, Donald A Wilson
Apolipoprotein E (ApoE) is an important lipid carrier in both the periphery and the brain. The ApoE ε4 allele (ApoE4) is the single most important genetic risk-factor for Alzheimer's disease (AD) while the ε 2 allele (ApoE2) is associated with a lower risk of AD-related neurodegeneration compared to the most common variant, ε 3 (ApoE3). ApoE genotype affects a variety of neural circuits; however, the olfactory system appears to provide early biomarkers of ApoE genotype effects. Here, we directly compared olfactory behavior and olfactory system physiology across all three ApoE genotypes in 6-month- and 12-month-old mice with targeted replacement for the human ApoE2, ApoE3, or ApoE4 genes...
April 17, 2018: Neuroscience
https://www.readbyqxmd.com/read/29678606/ketogenic-diet-high-intensity-interval-training-hiit-and-memory-training-in-the-treatment-of-mild-cognitive-impairment-a-case-study
#4
Kaitlyn Dahlgren, Kelly J Gibas
Alzheimer's disease (AD) deaths have increased by 89% since 2000. This alarming trajectory of neurological disease highlights the failure of current best practice. Deteriorating brain fuel supply is the nemesis of intact neurological health. Cerebral hypo-metabolism associated with AD occurs years before onset. Both the ketogenic diet and calorie restriction (fasting) lead to a compensatory rise in ketones to improve energy deficits in the brain derived from cerebral insulin resistance. Two forms of ketone bodies, β-hydroxybutyrate and acetoacetate, fuel the brain during starvation, fasting and strenuous exercise...
April 11, 2018: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/29676998/an-epigenetic-biomarker-of-aging-for-lifespan-and-healthspan
#5
Morgan E Levine, Ake T Lu, Austin Quach, Brian H Chen, Themistocles L Assimes, Stefania Bandinelli, Lifang Hou, Andrea A Baccarelli, James D Stewart, Yun Li, Eric A Whitsel, James G Wilson, Alex P Reiner, Abraham Aviv, Kurt Lohman, Yongmei Liu, Luigi Ferrucci, Steve Horvath
Identifying reliable biomarkers of aging is a major goal in geroscience. While the first generation of epigenetic biomarkers of aging were developed using chronological age as a surrogate for biological age, we hypothesized that incorporation of composite clinical measures of phenotypic age that capture differences in lifespan and healthspan may identify novel CpGs and facilitate the development of a more powerful epigenetic biomarker of aging. Using an innovative two-step process, we develop a new epigenetic biomarker of aging, DNAm PhenoAge, that strongly outperforms previous measures in regards to predictions for a variety of aging outcomes, including all-cause mortality, cancers, healthspan, physical functioning, and Alzheimer's disease...
April 18, 2018: Aging
https://www.readbyqxmd.com/read/29674420/white-matter-reference-region-in-pet-studies-of-11-c-pittsburgh-compound-b-uptake-effects-of-age-and-amyloid-%C3%AE-deposition
#6
Val J Lowe, Emily S Lundt, Matthew L Senjem, Christopher G Schwarz, Hoon-Ki Min, Scott A Przybelski, Kejal Kantarci, David Knopman, Ronald C Petersen, Clifford R Jack
Amyloid-β (Aβ) deposition as seen on positron emission tomography (PET) using an Aβ binding agent is a critical diagnostic biomarker for Alzheimer's disease (AD). Some reports suggest using white matter (WM) as a reference region for quantification of serial Aβ PET studies; however, nonspecific WM retention in Aβ PET in people with dementia or in cognitively unimpaired (CU) has been widely reported and is poorly understood. Methods: To investigate the suitability of WM as a reference region and the factors affecting WM 11 C-Pittsburgh Compound B (PiB) uptake variability, we conducted a retrospective study on two large data sets: 1) a longitudinal study of participants ( n = 577) who were CU, had mild cognitive impairment (MCI), or had dementia likely due to AD (ADD); and 2) a cross-sectional study of single-scan PET imaging in CU subjects ( n = 1349)...
April 19, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29674076/a-facile-route-to-glycated-albumin-detection
#7
Nadra Bohli, Olivier Meilhac, Philippe Rondeau, Syrine Gueffrache, Laurence Mora, Adnane Abdelghani
In this paper we propose an easy way to detect the glycated form of human serum albumin which is biomarker for several diseases such as diabetes and Alzheimer. The detection platform is a label free impedimetric immunosensor, in which we used a monoclonal human serum albumin antibody as a bioreceptor and electrochemical impedance as a transducing method. The antibody was deposited onto a gold surface by simple physisorption technique. Bovine serum albumin was used as a blocking agent for non-specific binding interactions...
July 1, 2018: Talanta
https://www.readbyqxmd.com/read/29674032/reliable-determination-of-new-lipid-peroxidation-compounds-as-potential-early-alzheimer-disease-biomarkers
#8
Ana García-Blanco, Carmen Peña-Bautista, Camille Oger, Claire Vigor, Jean-Marie Galano, Thierry Durand, Nuria Martín-Ibáñez, Miguel Baquero, Máximo Vento, Consuelo Cháfer-Pericás
Lipid peroxidation plays an important role in Alzheimer Disease, so corresponding metabolites found in urine samples could be potential biomarkers. The aim of this work is to develop a reliable ultra-performance liquid chromatography-tandem mass spectrometry analytical method to determine a new set of lipid peroxidation compounds in urine samples. Excellent sensitivity was achieved with limits of detection between 0.08 and 17 nmol L-1 , which renders this method suitable to monitor analytes concentrations in real samples...
July 1, 2018: Talanta
https://www.readbyqxmd.com/read/29672680/cognitive-correlates-of-%C3%AE-4%C3%AE-2-nicotinic-acetylcholine-receptors-in-mild-alzheimer-s-dementia
#9
Osama Sabri, Philipp M Meyer, Susanne Gräf, Swen Hesse, Stephan Wilke, Georg-Alexander Becker, Michael Rullmann, Marianne Patt, Julia Luthardt, Gudrun Wagenknecht, Alexander Hoepping, Rene Smits, Annegret Franke, Bernhard Sattler, Solveig Tiepolt, Steffen Fischer, Winnie Deuther-Conrad, Ulrich Hegerl, Henryk Barthel, Peter Schönknecht, Peter Brust
In early Alzheimer's dementia, there is a need for PET biomarkers of disease progression with close associations to cognitive dysfunction that may aid to predict further cognitive decline and neurodegeneration. Amyloid biomarkers are not suitable for that purpose. The α4β2 nicotinic acetylcholine receptors (α4β2-nAChRs) are widely abundant in the human brain. As neuromodulators they play an important role in cognitive functions such as attention, learning and memory. Post-mortem studies reported lower expression of α4β2-nAChRs in more advanced Alzheimer's dementia...
April 17, 2018: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29672663/analysis-of-long-noncoding-rnas-highlights-region-specific-altered-expression-patterns-and-diagnostic-roles-in-alzheimer-s-disease
#10
Meng Zhou, Hengqiang Zhao, Xinyu Wang, Jie Sun, Jianzhong Su
Increasing evidence has revealed the multiple roles of long noncoding RNAs (lncRNAs) in neurodevelopment, brain function and aging, and their dysregulation was implicated in many types of neurological diseases. However, expression pattern and diagnostic role of lncRNAs in Alzheimer's disease (AD) remain largely unknown and has gained significant attention. In this study, we performed a comparative analysis for lncRNA expression profiles in four brain regions in brain aging and AD. Our analysis revealed age- and disease-dependent region-specific lncRNA expression patterns in aging and AD...
April 17, 2018: Briefings in Bioinformatics
https://www.readbyqxmd.com/read/29667155/association-of-cerebrospinal-fluid-neurogranin-with-alzheimer-s-disease
#11
Lijun Wang
Cerebrospinal fluid (CSF) Neurogranin has recently been proposed as a potential biomarker for cognitive decline and brain injury in Alzheimer's disease (AD). To test whether CSF Neurogranin levels are increased in AD and its association with cognitive decline, we examined 99 cognitively normal (CN) subjects, 171 patients with mild cognitive impairment (MCI), and 81 patients with AD in the cross-sectional study from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The results showed that CSF Neurogranin was increased in both AD and MCI compared with controls...
April 17, 2018: Aging Clinical and Experimental Research
https://www.readbyqxmd.com/read/29663736/platelets-lymphocytes-and-erythrocytes-from-alzheimer-s-disease-patients-the-quest-for-blood-cell-based-biomarkers
#12
Ryszard Pluta, Marzena Ułamek-Kozioł, Sławomir Januszewski, Stanisław J Czuczwar
In elderly population, Alzheimer's disease is a common neurodegenerative disorder and accounts for about 70% of all cases of dementia. The neurodegenerative processes of this disease start presumably 20 years ahead of the clinical beginning of the disorder. The postmortem histopathological examination, brains from Alzheimer's disease patients with characteristic features like amyloid plaques and neurofibrillary tangles, neuronal and synaptic disintegration confirm the final diagnosis of Alzheimer's disease...
2018: Folia Neuropathologica
https://www.readbyqxmd.com/read/29660946/pet-tau-and-amyloid-%C3%AE-burden-in-mild-alzheimer-s-disease-divergent-relationship-with-age-cognition-and-cerebrospinal-fluid-biomarkers
#13
(no author information available yet)
No abstract text is available yet for this article.
2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29660934/bi-directional-association-of-cerebrospinal-fluid-immune-markers-with-stage-of-alzheimer-s-disease-pathogenesis
#14
Pierre-François Meyer, Melissa Savard, Judes Poirier, Anne Labonté, Pedro Rosa-Neto, Tara M Weitz, Terrence Town, John Breitner
Immune mechanisms may be important in the pathogenesis of Alzheimer's disease (AD). Yet, studies comparing healthy and demented individuals' cerebrospinal fluid (CSF) and plasma immune marker levels have yielded conflicting results. We analyzed CSF from 101 members of the parental history-positive PREVENT-AD cohort of healthy aging adults, and 237 participants in the initial cohort of the Alzheimer's Disease Neuroimaging Initiative (ADNI-1). Following recent practice, we used the biomarkers total-tau and amyloid-β1 - 42 to allocate participants from each study into four stages of AD pathogenesis: Stage 0 (no abnormality), Stage 1 (reduced amyloid-β1 - 42), Stage 2 (reduced amyloid-β1 - 42 and increased total-tau), or "Suspected Non-Alzheimer Pathology" (elevated total-tau only)...
April 11, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29656189/quantitative-electroencephalography-as-a-marker-of-cognitive-fluctuations-in-dementia-with-lewy-bodies-and-an-aid-to-differential-diagnosis
#15
Myrto Stylianou, Nicholas Murphy, Luis R Peraza, Sara Graziadio, Ruth Cromarty, Alison Killen, John T O' Brien, Alan J Thomas, Fiona E N LeBeau, John-Paul Taylor
OBJECTIVE: We investigated for quantitative EEG (QEEG) differences between Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) patients and healthy controls, and for QEEG signatures of cognitive fluctuations (CFs) in DLB. METHODS: We analysed eyes-closed, resting state EEGs from 18 AD, 17 DLB and 17 PDD patients with mild dementia, and 21 age-matched controls. Measures included spectral power, dominant frequency (DF), frequency prevalence (FP), and temporal DF variability (DFV), within defined EEG frequency bands and cortical regions...
April 3, 2018: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
https://www.readbyqxmd.com/read/29652815/olfactory-dysfunction-as-a-global-biomarker-for-sniffing-out-alzheimer-s-disease-a-meta-analysis
#16
Alisha M Kotecha, Angelo D C Corrêa, Kim M Fisher, Jo V Rushworth
Cases of Alzheimer's disease (AD) are rising exponentially due to increasing global life expectancy. There are approximately 50 million sufferers worldwide, with prevalence rising most rapidly in low-income countries such as Africa and Asia. There is currently no definite diagnosis of AD until after death, thus an early biomarker for AD is urgently required in order to administer timelier and more effective interventions. Olfactory dysfunction (problems with the sense of smell) is one of the earliest, preclinical symptoms observed in AD...
April 13, 2018: Biosensors
https://www.readbyqxmd.com/read/29651720/biomarkers-study-in-atypical-dementia-proof-of-a-diagnostic-work-up
#17
Gemma Lombardi, Cristina Polito, Valentina Berti, Camilla Ferrari, Giulia Lucidi, Silvia Bagnoli, Irene Piaceri, Benedetta Nacmias, Alberto Pupi, Sandro Sorbi
An early differentiation between Alzheimer's Disease (AD) and other dementias is crucial for an adequate patients' management, albeit it may result difficult for the occurrence of "atypical presentations." Current diagnostic criteria recognize the importance of biomarkers for AD diagnosis, but still an optimal diagnostic work-up isn't available. Evaluate the utility and reproducibility of biomarkers and propose an "optimal" diagnostic work-up in atypical dementia: (1) a retrospective selection of "atypical dementia cases"; (2) a repetition of diagnostic assessment by two neurologists following two different diagnostic work-ups, each consisting of multiple steps; (3) a comparison between diagnostic accuracy and confidence reached at each step by both neurologists and evaluation of the inter-rater agreement...
April 13, 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29651153/decipher-reliable-biomarkers-of-brain-aging-by-integrating-literature-based-evidence-with-interactome-data
#18
Sang-Hun Bae, Han Wool Kim, SeoJeong Shin, Joopyung Kim, Yun-Hwa Jeong, Jisook Moon
Aging is an inevitable progressive decline in every physiological function and serves as a primary risk factor for cognitive decline and Alzheimer's disease. Thus, age-dependent impairments in cognitive function must be understood in association with general aging processes with an integrative approach in a systemic manner. An integrative aging gene network was constructed based on mutual molecular interactions using literature-curated interactome data and separated into functionally distinct modules. To investigate key surrogate biomarkers of the aging brain in the context of the general aging process, co-expression networks were built on post-mortem and Alzheimer's brain transcriptome data...
April 13, 2018: Experimental & Molecular Medicine
https://www.readbyqxmd.com/read/29629537/different-associations-of-plasma-biomarkers-in-alzheimer-s-disease-mild-cognitive-impairment-vascular-dementia-and-ischemic-stroke
#19
Jingwei Shang, Toru Yamashita, Yusuke Fukui, Dongjing Song, Xianghong Li, Yun Zhai, Yumiko Nakano, Ryuta Morihara, Nozomi Hishikawa, Yasuyuki Ohta, Koji Abe
BACKGROUND AND PURPOSE: Cognitive and cerebrovascular diseases are common in the elderly, but differences in the plasma levels and associations of plasma biomarkers in these diseases remain elusive. METHODS: The present study investigated differences in plasma fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)], adiponectin, reptin, plasma markers of inflammation [high-sensitivity C-reactive protein (hsCRP) and serum amyloid A (serum AA)], and plasma lipids [high-density lipoprotein and low-density lipoprotein (LDL)] in patients with Alzheimer's disease (AD) (n=266), mild cognitive impairment (MCI) (n=44), vascular dementia (VaD) (n=33), and ischemic stroke (IS) (n=200) in comparison to normal controls (n=130)...
January 2018: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/29626426/plasma-phospho-tau181-increases-with-alzheimer-s-disease-clinical-severity-and-is-associated-with-tau-and-amyloid-positron-emission-tomography
#20
Michelle M Mielke, Clinton E Hagen, Jing Xu, Xiyun Chai, Prashanthi Vemuri, Val J Lowe, David C Airey, David S Knopman, Rosebud O Roberts, Mary M Machulda, Clifford R Jack, Ronald C Petersen, Jeffrey L Dage
INTRODUCTION: We examined and compared plasma phospho-tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ. METHODS: Participants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181...
April 4, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
keyword
keyword
16714
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"